743 related articles for article (PubMed ID: 26676771)
1. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
[TBL] [Abstract][Full Text] [Related]
2. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses.
Weger-Lucarelli J; Aliota MT; Kamlangdee A; Osorio JE
PLoS Negl Trop Dis; 2015; 9(10):e0004163. PubMed ID: 26473963
[TBL] [Abstract][Full Text] [Related]
3. Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization.
Thaa B; Biasiotto R; Eng K; Neuvonen M; Götte B; Rheinemann L; Mutso M; Utt A; Varghese F; Balistreri G; Merits A; Ahola T; McInerney GM
J Virol; 2015 Nov; 89(22):11420-37. PubMed ID: 26339054
[TBL] [Abstract][Full Text] [Related]
4. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice.
Ashbrook AW; Burrack KS; Silva LA; Montgomery SA; Heise MT; Morrison TE; Dermody TS
J Virol; 2014 Nov; 88(21):12180-92. PubMed ID: 25142598
[TBL] [Abstract][Full Text] [Related]
5. Ability of the Encephalitic Arbovirus Semliki Forest Virus To Cross the Blood-Brain Barrier Is Determined by the Charge of the E2 Glycoprotein.
Ferguson MC; Saul S; Fragkoudis R; Weisheit S; Cox J; Patabendige A; Sherwood K; Watson M; Merits A; Fazakerley JK
J Virol; 2015 Aug; 89(15):7536-49. PubMed ID: 25972559
[TBL] [Abstract][Full Text] [Related]
6. Role of TSPAN9 in Alphavirus Entry and Early Endosomes.
Stiles KM; Kielian M
J Virol; 2016 May; 90(9):4289-97. PubMed ID: 26865714
[TBL] [Abstract][Full Text] [Related]
7. Semliki Forest Virus Chimeras with Functional Replicase Modules from Related Alphaviruses Survive by Adaptive Mutations in Functionally Important Hot Spots.
Teppor M; Žusinaite E; Karo-Astover L; Omler A; Rausalu K; Lulla V; Lulla A; Merits A
J Virol; 2021 Sep; 95(20):e0097321. PubMed ID: 34319778
[TBL] [Abstract][Full Text] [Related]
8. Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
Erasmus JH; Seymour RL; Kaelber JT; Kim DY; Leal G; Sherman MB; Frolov I; Chiu W; Weaver SC; Nasar F
J Virol; 2018 Feb; 92(4):. PubMed ID: 29187545
[TBL] [Abstract][Full Text] [Related]
9. The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff.
Garmashova N; Gorchakov R; Volkova E; Paessler S; Frolova E; Frolov I
J Virol; 2007 Mar; 81(5):2472-84. PubMed ID: 17108023
[TBL] [Abstract][Full Text] [Related]
10. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
[TBL] [Abstract][Full Text] [Related]
11. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
[TBL] [Abstract][Full Text] [Related]
12. Molecular investigations of chikungunya virus during outbreaks in Orissa, Eastern India in 2010.
Das B; Sahu A; Das M; Patra A; Dwibedi B; Kar SK; Hazra RK
Infect Genet Evol; 2012 Jul; 12(5):1094-101. PubMed ID: 22484761
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.
Jones JE; Long KM; Whitmore AC; Sanders W; Thurlow LR; Brown JA; Morrison CR; Vincent H; Peck KM; Browning C; Moorman N; Lim JK; Heise MT
mBio; 2017 Nov; 8(6):. PubMed ID: 29138302
[TBL] [Abstract][Full Text] [Related]
14. Host oxidative folding pathways offer novel anti-chikungunya virus drug targets with broad spectrum potential.
Langsjoen RM; Auguste AJ; Rossi SL; Roundy CM; Penate HN; Kastis M; Schnizlein MK; Le KC; Haller SL; Chen R; Watowich SJ; Weaver SC
Antiviral Res; 2017 Jul; 143():246-251. PubMed ID: 28461071
[TBL] [Abstract][Full Text] [Related]
15. Cross-inhibition of chikungunya virus fusion and infection by alphavirus E1 domain III proteins.
Sánchez-San Martín C; Nanda S; Zheng Y; Fields W; Kielian M
J Virol; 2013 Jul; 87(13):7680-7. PubMed ID: 23637415
[TBL] [Abstract][Full Text] [Related]
16. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
[TBL] [Abstract][Full Text] [Related]
17. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization.
Silva LA; Khomandiak S; Ashbrook AW; Weller R; Heise MT; Morrison TE; Dermody TS
J Virol; 2014 Mar; 88(5):2385-97. PubMed ID: 24371059
[TBL] [Abstract][Full Text] [Related]
18. Genetic characterization of E2 region of Chikungunya virus circulating in Odisha, Eastern India from 2010 to 2011.
Sahu A; Das B; Das M; Patra A; Biswal S; Kar SK; Hazra RK
Infect Genet Evol; 2013 Aug; 18():113-24. PubMed ID: 23684629
[TBL] [Abstract][Full Text] [Related]
19. Infectious clones of Chikungunya virus (La Réunion isolate) for vector competence studies.
Tsetsarkin K; Higgs S; McGee CE; De Lamballerie X; Charrel RN; Vanlandingham DL
Vector Borne Zoonotic Dis; 2006; 6(4):325-37. PubMed ID: 17187566
[TBL] [Abstract][Full Text] [Related]
20. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
